Compassionate Use of REGEN|COV® in Patients With Coronavirus ...

Compassionate Use of REGEN-COV® in Patients With Coronavirus ...

In this retrospective analysis of immunodeficient patients granted REGEN-COV under emergency compassionate use, REGEN-COV treatment was ...

Compassionate Use of REGEN-COV® in Patients With Coronavirus ...

Patients With COVID-19 Duration of ≥21 Days Prior to Treatment. In total, 174 patients from the United States were evaluated and approved to receive REGEN-COV ...

Compassionate Use of REGEN-COV® in Patients with COVID-19 ...

Summary Patients with immunodeficiency-associated antibody disorders are at a higher risk of prolonged/persistent COVID-19 infection. In this ...

Compassionate Use of REGEN-COV ® in Patients with COVID-19 ...

Compassionate Use of REGEN-COV ® in Patients with COVID-19 and Immunodeficiency-Associated Antibody Disorders. David Stein,. Ernesto Oviedo-Orta,. Wendy A ...

Compassionate use of REGN-COV2 in the treatment of COVID-19 in ...

Prolonged COVID-19 infection may occur in patients with primary immunodeficiency. · Antiviral treatment alone may be insufficient in patients lacking humoral ...

Analysis of immunodeficient patients granted REGEN-COV under ...

Recently, the United States Food and Drug Administration (FDA) has granted compassionate use of REGEN-COV® for patients with COVID-19 and ...

Compassionate use of REGN-COV2 in the treatment of COVID-19 in ...

This case highlights the role of antibodies in clearing SARS-CoV-2 in a hypogammaglobulinaemic host and demonstrates the consequences of prolonged ...

Compassionate Use of REGEN-COV ® in Patients with COVID-19 ...

Summary Patients with immunodeficiency-associated antibody disorders are at a higher risk of prolonged/persistent COVID-19 infection. In this retrospective ...

Compassionate Use of REGEN-COV(R) in Patients with COVID-19 ...

Background: Patients with immunodeficiency-associated antibody disorders are at a higher risk of prolonged/persistent coronavirus disease ...

Compassionate Use of REGEN-COV ® in Patients with COVID-19 ...

Thirty-seven of these had COVID-19 duration ≥21 days before treatment; median time from diagnosis to REGEN-COV was 60.5 days. Of the 29 patients with COVID-19 ...

Compassionate Use of REGEN-COV® in Patients With Coronavirus ...

REGEN-COV treatment was associated with rapid viral clearance and clinical improvement in the evaluable patients with long-standing COVID-19, ...

New Phase 3 Analyses Show That a Single Dose of REGEN-COV ...

Regeneron Pharmaceuticals, Inc. ... "Today's new data demonstrate how a single dose of REGEN-COV can help protect people from COVID-19 for many ...

REGEN-COV Antibody Combination and Outcomes in Outpatients ...

Although most patients with Covid-19 receive care in the outpatient setting, some have disease that progresses to severe illness leading to ...

Regeneron EUA HCP Fact Sheet 01242022 - FDA

1. • REGEN-COV (casirivimab and imdevimab) is not authorized for use in patients: o who are hospitalized due to COVID-19, OR o who require oxygen therapy due to ...

Phase 3 Treatment Trial in Recently Infected Asymptomatic Patients ...

Therefore, REGEN-COV is not authorized for use in patients who are hospitalized due to COVID-19, OR who require oxygen therapy due to COVID-19, ...

Compassionate Use of Remdesivir for Patients with Severe Covid-19

We provided remdesivir on a compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection with SARS-CoV-2.

Compassionate Use of REGEN-COV® in Patients With Coronavirus ...

Compassionate Use of REGEN-COV® in Patients With Coronavirus Disease 2019 (COVID-19) and Immunodeficiency-Associated Antibody Disorders · Clinical Infectious ...

fact sheet for patients, parents and caregivers emergency - FDA

EMERGENCY USE AUTHORIZATION (EUA) OF REGEN-COVTM. (casirivimab and imdevimab) FOR CORONAVIRUS DISEASE 2019 (COVID-19). You are being given a medicine called ...

EMA provides recommendations on compassionate use of ...

Remdesivir has been shown to be active against SARS-CoV-2 and other types of coronavirus (i.e. SARS-CoV and MERS-CoV) in laboratory studies; ...

Effectiveness of REGEN-COV antibody combination in preventing ...

-risk patients infected with SARS-CoV-2 within five days of their diagnosis. We performed a retrospective cohort study, and used data ...